<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/C1ED9692-B6AE-4778-BF31-AE813E8E4415"><gtr:id>C1ED9692-B6AE-4778-BF31-AE813E8E4415</gtr:id><gtr:name>MRC Prion Unit</gtr:name><gtr:address><gtr:line1>MRC Prion Unit</gtr:line1><gtr:line2>Institute of Neurology</gtr:line2><gtr:line3>Queen Square</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>WC1N 3BG</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C1ED9692-B6AE-4778-BF31-AE813E8E4415"><gtr:id>C1ED9692-B6AE-4778-BF31-AE813E8E4415</gtr:id><gtr:name>MRC Prion Unit</gtr:name><gtr:address><gtr:line1>MRC Prion Unit</gtr:line1><gtr:line2>Institute of Neurology</gtr:line2><gtr:line3>Queen Square</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>WC1N 3BG</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/53323344-3564-46B0-BF9D-68BCA2496856"><gtr:id>53323344-3564-46B0-BF9D-68BCA2496856</gtr:id><gtr:firstName>Parmjit</gtr:firstName><gtr:surname>Jat</gtr:surname><gtr:orcidId>0000-0002-3354-0594</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_UP_1004%2F1"><gtr:id>28FA3688-763D-4E1B-B8FD-31FD6B18E43A</gtr:id><gtr:title>Cellular Functions of PrP</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_UP_1004/1</gtr:grantReference><gtr:abstractText>Prion diseases are fatal progressive neurodegenerative disorders that, like Alzheimer?s and Huntington?s disease, involve accumulation of a misfolded protein. This protein, the prion protein, is normally expressed within most cells of the body but the highest expression is within the brain and in the immune system. It is predominantly found on the surface of cells attached to the plasma membrane via a carbohydrate containing fatty acid linker. 
The prion protein has been proposed to have many cellular functions but is has been found that mice that are null for this protein are viable, do not have any overt symptoms but are completely resistant to prion disease. Even though the cellular prion protein is a prerequisite for prion disease, it is not known which parts of this protein are required for prion propagation. 

We aim to investigate which regions of the prion protein are required for propagating prions. We also aim to develop cells which can be used to propagate human prions since there are currently no cell lines which can propagate human prions. We also aim set up a primary cell assay to demonstrate that prions can kill neurones and use it to isolate and characterise the toxic species in prion disease.</gtr:abstractText><gtr:technicalSummary>According to the widely accepted protein-only hypothesis, prions comprise aggregated forms of misfolded host-encoded cellular prion protein (PrPC) generally referred to as PrPSc. PrPC is a glycosyl phosphatidylinositol (GPI)-anchored cell-surface glycoprotein, expressed in most cell types and tissues, but at the highest levels in the CNS and immune system. PrPC is highly conserved in mammals but a precise cellular function remains unclear although multiple functions have been proposed. However mice, in which the PrP gene has been knocked out, have no overt phenotype and a normal lifespan, but do not propagate prions and are completely resistant to prion disease, indicating that PrPC expression is absolutely required for prion propagation and prion-induced neurotoxicity. 

Like most GPI-anchored proteins, PrPC is predominantly found at the cell surface in lipid rafts which has led to the suggestion that it may be involved in signal transduction by acting as a cell-surface receptor. Since PrPC lacks a transmembrane domain for transmitting signals from the cell surface to the inside of the cell, much work has been done to identify binding partners that could transmit the signal from the cell surface to the cell interior. A number of putative binding partners have been identified but the biological significance of many of them is unclear since some are only present within the cytoplasm, whereas others are nuclear. Recent evidence has suggested that PrPC acts as a cell surface receptor for A?-oligomers, the molecular species that mediate toxicity in Alzheimer?s disease. PrPC is also widely expressed in the immune system where it has been suggested to play a role in homeostasis as well as in the immune synapse and signalling. 

We have undertaken a reverse genetic approach, utilising alanine mutagenesis, to investigate the regions of PrPC that are required for efficient prion propagation in PK1 cells, a derivative of N2a neuroblastoma cells. This has identified three regions within the unstructured N-terminus as critical for prion propagation: residues 23-25 (KKR, Charge Cluster 1), glutamine 41 and residues 90-111 (Charge Cluster 2). Our aim is now to identify the proteins that interact with these regions. 

We also aim to develop cells that can efficiently propagate human sCJD and vCJD prions to set up an automated bioassay for human prions that can be used as a therapeutic biomarker. We will also develop a primary neuronal cell assay for prion neurotoxicity that will be applied to isolate and characterise the putative toxic PrP species.</gtr:technicalSummary><gtr:fund><gtr:end>2017-05-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2014-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>1513801</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Prion Conference</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>7776373E-2EE3-4CFE-8204-1DAFB1256891</gtr:id><gtr:impact>Annual International Prion conference where researchers from all the world come to present their latest research.</gtr:impact><gtr:outcomeId>58c283d213e7b2.81541664</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014,2015,2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>70334</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Commonwealth Scholarship Commission</gtr:department><gtr:description>Commonwealth Scholarship</gtr:description><gtr:end>2018-09-02</gtr:end><gtr:fundingOrg>Government of the UK</gtr:fundingOrg><gtr:fundingRef>CSC Reference Number: INCS-2014-212</gtr:fundingRef><gtr:id>C9CBA3C6-6DCE-4060-BD96-0672A01197B4</gtr:id><gtr:outcomeId>56ddb673469926.93220185</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2015-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>75000</gtr:amountPounds><gtr:country>Mexico, United Mexican States</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CONACyT Mexican PhD Scholarship</gtr:description><gtr:end>2018-01-02</gtr:end><gtr:fundingOrg>Oportunidades (Mexican Government)</gtr:fundingOrg><gtr:fundingRef>329734</gtr:fundingRef><gtr:id>F41054F1-5199-464B-8EFB-AFD0F471F727</gtr:id><gtr:outcomeId>56ddb85095d2b5.81331531</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2015-02-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>1BE60982-0656-43AE-8E7B-336E6E25B3F7</gtr:id><gtr:title>In vitro screen of prion disease susceptibility genes using the scrapie cell assay.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9e14ad7dc46751cc03b82cf6e81f69dc"><gtr:id>9e14ad7dc46751cc03b82cf6e81f69dc</gtr:id><gtr:otherNames>Brown CA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>545a5d14342232.51503724</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9EE75B01-3CAF-4E92-AD4D-C87F072FF9D3</gtr:id><gtr:title>A systematic investigation of production of synthetic prions from recombinant prion protein.</gtr:title><gtr:parentPublicationTitle>Open biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7b2740857e0a6a774e56992f6a12381e"><gtr:id>7b2740857e0a6a774e56992f6a12381e</gtr:id><gtr:otherNames>Schmidt C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2046-2441</gtr:issn><gtr:outcomeId>56dab60b9553a4.82786959</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EB755B19-D383-47A9-9257-215928FDA18E</gtr:id><gtr:title>Identification of clinical target areas in the brainstem of prion-infected mice.</gtr:title><gtr:parentPublicationTitle>Neuropathology and applied neurobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3b4a14d045add76c8604dba0817e1bf2"><gtr:id>3b4a14d045add76c8604dba0817e1bf2</gtr:id><gtr:otherNames>Mirabile I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0305-1846</gtr:issn><gtr:outcomeId>545a5d14c3bbf0.08971691</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_UP_1004/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>